Predictive Oncology (NASDAQ: POAI) has announced a new chief business officer. Effective immediately, Pamela Bush, PhD, MBA, will take on the role as chief business officer and will oversee all business development including the partnering and growth strategies for the company. Specifically, the company observed that she will manage the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets, working closely with POAI senior management to leverage and expand the company’s growing portfolio of proprietary solutions designed to advance drug discovery and enable oncology drug development for the company’s biopharma partners. Prior to this new appointment, Bush served as senior VP of strategic sales and business development at Predictive Oncology, guiding the company’s strategic direction, expanding its product offerings and launching commercialization efforts for the company’s flagship technology platform. In a statement, Bush said she looks forward to “further impacting the future of oncology drug discovery and driving adoption of solutions that can move compounds into clinical trials faster and with higher confidence.” Bush has an impressive background, with more than two decades of experience in venture creation, finance and business development in the life sciences industry. Before POAI, she worked at Eli Lilly & Company in various roles including director of immunology and director of corporate business development; she has also been involved in the creation and growth of more than 100 life sciences start-ups. “In terms of scientific intelligence, industry insight and understanding the business of biopharma, Pamela is at the top of her game,” said Predictive Oncology CEO and board chair Raymond F. Vennare in the press release. “She honed these skills over 20 years of experience analyzing emerging markets in life sciences, capital formation for early-stage companies and, most recently, leading business development efforts for Eli Lilly & Company.”
To view the full press release, visit https://ibn.fm/HeW2y
About Predictive Oncology Inc.
Predictive Oncology, a science-driven company on the leading edge of oncology drug discovery, offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of more than 150,000 tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.